1887
  1. Home
  2. A-Z Publications
  3. Journal of Emergency Medicine, Trauma and Acute Care
  4. Volume 2023, Issue 4
  5. Article
Volume 2023, Issue 4
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

The liver heals remarkably after different forms of injury. However, healing can be lengthy following high-grade injuries. We hypothesize that injected mesenchymal stem cells (MSCs) could locate in the liver and differentiate into hepatocytes after blunt trauma using a rat liver trauma model.

Blunt liver trauma was induced in Lewis rats. MSCs were transfected with LacZ retrovirus so that they express the beta-galactosidase enzyme, giving their nuclei a blue color on light microscopy. Each rat received a dose of MSCs ( = 6 × 106) within 24 h of trauma. Through different steps of the experiment, the route of injection was the tail vein (TV) in nine rats, the portal vein (PV) in 19 rats, and directly to the injured liver (DI) in four rats. Rats were euthanized at 48 h or 7 days after the injection of MSCs. Livers were harvested and examined under light microscopy to identify the MSCs.

Liver sections showed localization and migration of MSCs to trauma sites in the PV group euthanized at 48 h (3/10 rats). Some MSCs differentiated into hepatocytes. Similar findings were present in 1/9 rats euthanized at 7 days in the PV group. There was no evidence of MSC localization in TV and DI groups.

Discussion: MSCs can locate and differentiate into liver-like cells in blunt liver injury. Portal vein injection of MSC has emerged as the most effective method of delivery to the liver among the other methods. Optimizing homing to injured tissue and evaluating differentiated stem cell functionality are future areas of research.

© 2023 Alhabboubi, Grushka, Gao, Deckelbaum, Razek, Shum-Tim, Duong, Khwaja, Licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2023.39
2023-12-06
2024-04-29
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2023/4/jemtac.2023.39.html?itemId=/content/journals/10.5339/jemtac.2023.39&mimeType=html&fmt=ahah

References

  1. David Richardson J, Franklin GA, Lukan JK, Carrillo EH, Spain DA, Miller FB, et al. Evolution in the management of hepatic trauma: A 25-year perspective. Ann Surg. 2000; 232:(3):324–30.
     [Google Scholar]
  2. Croce MA, Fabian TC, Menke PG, Waddle-Smith L, Minard G, Kudsk KA, et al. Nonoperative management of blunt hepatic trauma is the treatment of choice for hemodynamically stable patients. Results of a prospective trial. Ann Surg. 1995; 221:(6):744–53; discussion 53–5.
     [Google Scholar]
  3. Malhotra AK, Fabian TC, Croce MA, Gavin TJ, Kudsk KA, Minard G, et al. Blunt hepatic injury: A paradigm shift from operative to nonoperative management in the 1990s. Ann Surg. 2000; 231:(6):804–13.
     [Google Scholar]
  4. Mattox KL. EE, Feliciano DV. Trauma 9th ed. Chapter 33: Liver and Biliary Tract, Brandon Bruns, Rosemary Kozar. McGraw Hill.
     [Google Scholar]
  5. Kozar RA, Moore FA, Cothren CC, Moore EE, Sena M, Bulger EM, et al. Risk factors for hepatic morbidity following nonoperative management: Multicenter study. rch Surg. 2006; 141:(5):451–8; discussion 8–9.
     [Google Scholar]
  6. Asensio JA, Roldan G, Petrone P, Rojo E, Tillou A, Kuncir E, et al. Operative management and outcomes in 103 AAST-OIS grades IV and V complex hepatic injuries: Trauma surgeons still need to operate, but angioembolization helps. J Trauma. 2003; 54:(4):647–53; discussion 53–4.
     [Google Scholar]
  7. Padalino P, Bomben F, Chiara O, Montagnolo G, Marini A, Zago M, et al. Healing of blunt liver injury after non-operative management: Role of ultrasonography follow-up. Eur J Trauma Emerg Surg. 2009; 35:(4):364–70.
     [Google Scholar]
  8. Stassen NA, Bhullar I, Cheng JD, Crandall M, Friese R, Guillamondegui O, et al. Nonoperative management of blunt hepatic injury: An Eastern Association for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg. 2012; 73:(5 Suppl. 4):S288–93.
     [Google Scholar]
  9. Mattox KL, Moore EE, Feliciano DV. Trauma. In: Liver and Biliary Tract. th ed. McGraw-Hill Companies; 2013.
     [Google Scholar]
  10. Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007; 40:(12):893–9.
     [Google Scholar]
  11. Bellayr IH, Gharaibeh B, Huard J, Li Y. Skeletal muscle-derived stem cells differentiate into hepatocyte-like cells and aid in liver regeneration. Int J Clin Exp Pathol. 2010; 3:(7):681–90.
     [Google Scholar]
  12. Zhao W, Li JJ, Cao DY, Li X, Zhang LY, He Y, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol 2012; 18:(10):1048–58.
     [Google Scholar]
  13. Yu Y, Yao AH, Chen N, Pu LY, Fan Y, Lv L, et al. Mesenchymal stem cells over-expressing hepatocyte growth factor improve small-for-size liver grafts regeneration. Mol Ther. 2007; 15:(7):1382–9.
     [Google Scholar]
  14. Liu WH, Song FQ, Ren LN, Guo WQ, Wang T, Feng YX, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med. 2015; 19:(3):511–20.
     [Google Scholar]
  15. Cox JM, Kalns JE. Development and characterization of a rat model of nonpenetrating liver trauma. Comp Med. 2010; 60:(3):218–24.
     [Google Scholar]
  16. Jun L, Minh D, Calvin W, Carolyn JT, Ray CJC, Dominique ST. The immature heart: The roles of bone marrow stromal stem cells in growth and myocardial repair. Open Cardiovasc Med J. 2007; 1::27–33.
     [Google Scholar]
  17. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006; 24:(10):2292–8.
     [Google Scholar]
  18. Eom YW, Kang SH, Kim MY, Lee JI, Baik SK. Mesenchymal stem cells to treat liver diseases. Ann Transl Med. 2020; 8:(8):563.
     [Google Scholar]
  19. Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 2015; 30:(5):580–9.
     [Google Scholar]
  20. Cuesta-Gomez N, Graham GJ, Campbell JDM. Chemokines and their receptors: Predictors of the therapeutic potential of mesenchymal stromal cells. J Transl Med. 2021; 19:(1):156.
     [Google Scholar]
  21. Brooke G, Tong H, Levesque JP, Atkinson K. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev. 2008; 17:(5):929–40.
     [Google Scholar]
  22. Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie. 2013; 95:(12):2196–211.
     [Google Scholar]
  23. Liu H, Liu DQ, Li BW, Guan LD, Yan ZF, Li YL, et al. Human amniotic fluid-derived stem cells can differentiate into hepatocyte-like cells in vitro and in vivo. In Vitro Cell Dev Biol Anim. 2011; 47:(9):601–8.
     [Google Scholar]
  24. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev. 2009; 18:(5):683–92.
     [Google Scholar]
  25. Li Z, Hu X, Mao J, Liu X, Zhang L, Liu J, et al. Optimization of mesenchymal stem cells (MSCs) delivery dose and route in mice with acute liver injury by bioluminescence imaging. Mol Imaging Biol. 2015; 17:(2):185–94.
     [Google Scholar]
  26. Sgodda M, Aurich H, Kleist S, Aurich I, Konig S, Dollinger MM, et al. Hepatocyte differentiation of mesenchymal stem cells from rat peritoneal adipose tissue in vitro and in vivo. Exp Cell Res. 2007; 313:(13):2875-86.
     [Google Scholar]
  27. Xiang GA, Zhang GQ, Fang CH, Gao P, Chen KY. [A preliminary study of the homing capacity of allograft mesenchymal stem cells to rat liver]. Di Yi Jun Yi Da Xue Xue Bao. 2005; 25:(8):994–7.
     [Google Scholar]
  28. Sang JF, Shi XL, Han B, Huang T, Huang X, Ren HZ, et al. Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis. Hepatobiliary Pancreat Dis Int. 2016; 15:(6):602–11.
     [Google Scholar]
  29. Wang Y, Lian F, Li J, Fan W, Xu H, Yang X, et al. Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats. J Transl Med. 2012; 10::133.
     [Google Scholar]
  30. Li Q, Zhou X, Shi Y, Li J, Zheng L, Cui L, et al. In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury. PLoS One. 2013; 8:(4):e62363.
     [Google Scholar]
  31. Duncan AW, Dorrell C, Grompe M. Stem cells and liver regeneration. Gastroenterology. 2009; 137:(2):466–81.
     [Google Scholar]
  32. Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, et al. Stem cell therapy for liver disease: Parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008; 134:(7):2111–21, 21.e1–3.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2023.39
Loading
Injection of rat mesenchymal stem cells leads to their homing and differentiation in the liver in a blunt liver trauma model
Journal of Emergency Medicine, Trauma and Acute Care 2023, 39 (2023); https://doi.org/10.5339/jemtac.2023.39
/content/journals/10.5339/jemtac.2023.39
/content/journals/10.5339/jemtac.2023.39
Loading

Data & Media loading...

Keyword(s): mesenchymal stem cells and trauma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error